{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:44:36Z","timestamp":1761921876761,"version":"build-2065373602"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0863_abs_001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several guidelines groups have made recommendations about how to use natriuretic peptides (NPs) to screen patients with diabetes for incipient heart failure. This group is at risk for undetected and stage B heart failure, where structural heart disease is present despite the absence of clinical signs and symptoms. These recommendations are based on trial data that suggest there are therapeutic options to benefit these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0863_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>These guidelines do not adequately account for the marked analytic differences between NP assays nor their high degree of biological and analytical variability. Thus, without additional data and guidance, these recommendations could lead to excessive testing for some groups but might disadvantage others. In addition, these issues could lead to difficulties in the interpretation of values. Accordingly, the Committee on Clinical Applications of Cardiac Bio Markers of the International Federation of Clinical Chemistry has developed a consensus educational document to describe these difficulties and define areas where additional data are needed. Clinicians should be cognizant of differences in the assays for NPs, the high degree of variability of values, differences in sex and ethnicity and the need to factor in a variety of clinical and treatment variables in interpreting NP values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0863_abs_003\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>These suggestions for diabetes eventually will include others at high risk. They will require close attention to the issues involved in measuring and interpreting NP values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0863","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T14:58:35Z","timestamp":1754924315000},"page":"2130-2139","source":"Crossref","is-referenced-by-count":0,"title":["Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB)"],"prefix":"10.1515","volume":"63","author":[{"given":"Allan S.","family":"Jaffe","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine , 4352 Mayo Clinic , Rochester , MN , USA"},{"name":"Department of Laboratory Medicine and Pathology , Mayo Clinic , Rochester , MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yader","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Minneapolis Heart Institute, Abbott Northwestern Hospital, and Center for Coronary Artery Disease, Minneapolis Heart Institute Foundation , Minneapolis , MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas L.","family":"Mills","sequence":"additional","affiliation":[{"name":"BHF Centre for Cardiovascular Science , University of Edinburgh , Edinburgh , UK"},{"name":"Usher Institute, University of Edinburgh , Edinburgh , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torbj\u00f8rn","family":"Omland","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division of Medicine , Akershus University Hospital , L\u00f8renskog , Norway"},{"name":"K.G. Jebsen Center for Cardiac Biomarkers , Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7340-6736","authenticated-orcid":false,"given":"Kristin M.","family":"Aakre","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Pharmacology and Department of Heart Disease , Haukeland University Hospital , Bergen , Norway"},{"name":"Department of Clinical Science , University of Bergen , Bergen , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025103114402230433_j_cclm-2025-0863_ref_001","doi-asserted-by":"crossref","unstructured":"Sudoh, T, Kangawa, K, Minamino, N, Matsuo, H. A new natriuretic peptide in porcine brain. Nature 1988;332:78\u201381. https:\/\/doi.org\/10.1038\/332078a0.","DOI":"10.1038\/332078a0"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_002","doi-asserted-by":"crossref","unstructured":"Mukoyama, M, Nakao, K, Hosoda, K, Suga, S, Saito, Y, Ogawa, Y, et al.. Brain natriuretic peptide as a novel cardiac hormone in humans, evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. JCI 1991;87:1402\u201312. https:\/\/doi.org\/10.1172\/jci115146.","DOI":"10.1172\/JCI115146"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_003","doi-asserted-by":"crossref","unstructured":"McDonagh, TA, Robb, SD, Murdoch, DR, Morton, JJ, Ford, I, Morrison, CE, et al.. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9\u201313. https:\/\/doi.org\/10.1016\/s0140-6736-97-03034-1.","DOI":"10.1016\/S0140-6736(97)03034-1"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_004","doi-asserted-by":"crossref","unstructured":"Omland, T, Persson, A, Ng, L, O\u2019Brien, R, Karlsson, T, Herlitz, J, et al.. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913\u20138. https:\/\/doi.org\/10.1161\/01.cir.0000041661.63285.ae.","DOI":"10.1161\/01.CIR.0000041661.63285.AE"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_005","doi-asserted-by":"crossref","unstructured":"Hunt, PJ, Yandle, TG, Nicholls, MG, Richards, AM, Espiner, EA. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1173\u201383. https:\/\/doi.org\/10.1006\/bbrc.1995.2410.","DOI":"10.1006\/bbrc.1995.2410"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_006","doi-asserted-by":"crossref","unstructured":"Maisel, AS, Krishnaswamy, P, Nowak, RM, McCord, J, Hollander, JE, Duc, P, et al.. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N\u00a0Engl J Med 2002;347:161\u20137. https:\/\/doi.org\/10.1056\/nejmoa020233.","DOI":"10.1056\/NEJMoa020233"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_007","doi-asserted-by":"crossref","unstructured":"Januzzi, JLJ, Camargo, CA, Anwaruddin, S, Baggish, AL, Chen, AA, Krauser, DG, et al.. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948\u2013954, 956. https:\/\/doi.org\/10.1016\/j.amjcard.2004.12.032.","DOI":"10.1016\/j.amjcard.2004.12.032"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_008","doi-asserted-by":"crossref","unstructured":"Hawkridge, AM, Heublein, DM, Bergen, HR, Cataliotti, A, Burnett, JC, Muddiman, DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005;102:17442\u20137. https:\/\/doi.org\/10.1073\/pnas.0508782102.","DOI":"10.1073\/pnas.0508782102"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_009","doi-asserted-by":"crossref","unstructured":"Miller, WL, Phelps, MA, Wood, CM, Schellenberger, U, Le, AV, Perichon, R, et al.. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:355\u201360. https:\/\/doi.org\/10.1161\/circheartfailure.110.960260.","DOI":"10.1161\/CIRCHEARTFAILURE.110.960260"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_010","doi-asserted-by":"crossref","unstructured":"Seferian, KR, Tamm, NN, Semenov, AG, Mukharyamova, KS, Tolstaya, AA, Koshkina, EV, et al.. The brain natriuretic peptide (BNP) precursoris the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866\u201373. https:\/\/doi.org\/10.1373\/clinchem.2006.076141.","DOI":"10.1373\/clinchem.2006.076141"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_011","doi-asserted-by":"crossref","unstructured":"Apple, FS, Writing Group, Wu, AH, Jaffe, AS, Panteghini, M, Christenson, RH, et al.. National academy of clinical biochemistry, IFCC committee for standardization of markers of cardiac damage laboratory medicine. National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 2007;116:e95\u20138. https:\/\/doi.org\/10.1161\/circulationaha.107.185266.","DOI":"10.1161\/CIRCULATIONAHA.107.185266"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_012","doi-asserted-by":"crossref","unstructured":"Saenger, AK, Rodriguez-Fraga, O, Ler, R, Ordonez-Llanos, J, Jaffe, A, Goetze, JP, et al.. Specificity of BType natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides. Clin Chem 2017;63:351\u20138. https:\/\/doi.org\/10.1373\/clinchem.2016.263749.","DOI":"10.1373\/clinchem.2016.263749"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_013","doi-asserted-by":"crossref","unstructured":"Wang, TJ, Larson, MG, Levy, D, Benjamin, EJ, Leip, EP, Omland, T, et al.. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N\u00a0Engl J Med 2004;350:655\u201363. https:\/\/doi.org\/10.1056\/nejmoa031994.","DOI":"10.1056\/NEJMoa031994"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_014","doi-asserted-by":"crossref","unstructured":"de Lemos, JA, McGuire, DK, Khera, A, Das, SR, Murphy, SA, Omland, R, et al.. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas heart study. Am Heart J 2009;157:746\u201353. https:\/\/doi.org\/10.1016\/j.ahj.2008.12.017.","DOI":"10.1016\/j.ahj.2008.12.017"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_015","doi-asserted-by":"crossref","unstructured":"Neeland, I, Drazner, MH, Berry, JD, Ayers, CR, deFilippi, C, Seliger, SL, et al.. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. JACC 2013;61:187\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.012.","DOI":"10.1016\/j.jacc.2012.10.012"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_016","doi-asserted-by":"crossref","unstructured":"A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines, Bozkurt, B, Aguilar, D, Allen, LA, Byun, JJ, Colvin, MM, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J\u00a0Am Coll Cardiol 2022;79:e263\u2013e421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_017","doi-asserted-by":"crossref","unstructured":"Nambi, V, Liu, X, Chambless, LE, de Lemos, JA, Virani, S, Agarwal, S, et al.. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk: the atherosclerosis risk in communities study. Clin Chem 2013;59:1802\u201310. https:\/\/doi.org\/10.1373\/clinchem.2013.203638.","DOI":"10.1373\/clinchem.2013.203638"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_018","doi-asserted-by":"crossref","unstructured":"McKie, PM, AbouEzzeddine, OF, Scott, CG, Mehta, R, Rodeheffer, RJ, Redfield, MM, et al.. High-sensitivity troponin I and amino-terminal pro-B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem 2014;60:1225\u201333. https:\/\/doi.org\/10.1373\/clinchem.2014.222778.","DOI":"10.1373\/clinchem.2014.222778"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_019","doi-asserted-by":"crossref","unstructured":"Natriuretic Peptides Studies Collaboration, Kaptoge, S, Welsh, P, Butterworth, AS, Chowdhury, R, Spackman, SA, et al.. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabet Endocrinol 2016;4:840\u20139. https:\/\/doi.org\/10.1016\/s2213-8587-16-30196-6.","DOI":"10.1016\/S2213-8587(16)30196-6"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_020","doi-asserted-by":"crossref","unstructured":"Than, MP, Aldous, SJ, Troughton, RW, Pemberton, CJ, Richards, AM, Frampton, CM, et al.. Detectable high-sensitivity cardiac troponin within the population reference interval conveys high 5-year cardiovascular risk: an observational study. Clin Chem 2018;64:1044\u201353. https:\/\/doi.org\/10.1373\/clinchem.2017.285700.","DOI":"10.1373\/clinchem.2017.285700"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_021","doi-asserted-by":"crossref","unstructured":"Sandoval, Y, Bielinski, SJ, Daniels, LB, Blaha, MJ, Michos, ED, DeFilippis, AP, et al.. Atherosclerotic cardiovascular disease risk stratification based on measurements of troponin and coronary artery calcium. J\u00a0Am Coll Cardiol 2020;76:357\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.057.","DOI":"10.1016\/j.jacc.2020.05.057"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_022","doi-asserted-by":"crossref","unstructured":"Ledwidge, M, Gallagher, J, Conlon, C, Tallon, E, O\u2019Connell, E, Litt, M, et al.. Natriuretic peptide based screening and collaborative care for heart failure: the STOP-HF randomized trial. J\u00a0Am Med Assoc 2013;310:66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588.","DOI":"10.1001\/jama.2013.7588"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_023","doi-asserted-by":"crossref","unstructured":"Huelsmann, M, Neuhold, S, Resl, M, Strunk, G, Brath, H, Francesconi, C, et al.. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease) a prospective randomized controlled trial. JACC 2013;62:1365\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.069.","DOI":"10.1016\/j.jacc.2013.05.069"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_024","doi-asserted-by":"crossref","unstructured":"Bayes-Genis, A, Docherty, KF, Petrie, MC, Januzzi, JL, Mueller, C, Anderson, L, et al.. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC. Eur J Heart Fail 2023;25:1891\u20138. https:\/\/doi.org\/10.1002\/ejhf.3036.","DOI":"10.1002\/ejhf.3036"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_025","doi-asserted-by":"crossref","unstructured":"Foy, BH, Petherbridge, R, Maxwell, T, Zhang, C, De Souza, DC, Mow, C, et al.. Haematological setpoints are a stable and patient-specific deep phenotype. Nature 2025;637:430\u20138. https:\/\/doi.org\/10.1038\/s41586-024-08264-5.","DOI":"10.1038\/s41586-024-08264-5"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_026","doi-asserted-by":"crossref","unstructured":"Aakre, KM, R\u00f8raas, T, Petersen, PH, Svarstad, E, S\u00e6le, K, Sandberg, S. Week-to-Week biological variation in the N-terminal prohormone of brain natriuretic peptide in hemodialysis patients and healthy individuals. Clin Chem 2013;59:1813\u201316. https:\/\/doi.org\/10.1373\/clinchem.2013.209353.","DOI":"10.1373\/clinchem.2013.209353"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_027","doi-asserted-by":"crossref","unstructured":"Wu, AHB, Smith, A, Wieczorek, S, Mather, JF, Duncan, B, White, CM, et al.. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628\u201331. https:\/\/doi.org\/10.1016\/s0002-9149-03-00741-0.","DOI":"10.1016\/S0002-9149(03)00741-0"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_028","doi-asserted-by":"crossref","unstructured":"Ellis, KL, Newton-Cheh, KL, Wang, TJ, Frampton, CM, Doughty, RN, Whalley, GA, et al.. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J\u00a0Mol Cell Cardiol 2011;50:695\u2013701. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.01.010.","DOI":"10.1016\/j.yjmcc.2011.01.010"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_029","doi-asserted-by":"crossref","unstructured":"Magnussin, M, Lyngbakken, MN, Kvisvik, B, Aagaard, EN, Berge, T, Pervez, M, et al.. B-Type natriuretic peptide is associated with indices of left ventricular dysfunction in healthy subjects from the general population: the Akershus cardiac examination 1950 study. Clin Chem 2021;67:204\u201315. https:\/\/doi.org\/10.1093\/clinchem\/hvaa257.","DOI":"10.1093\/clinchem\/hvaa257"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_030","doi-asserted-by":"crossref","unstructured":"Januzzi, JJL, Xu, J, Li, JW, Shaw, W, Oh, R, Pfeifer, M, et al.. Effects of canagliflozin on amino-terminal Pro-B-Type natriuretic peptide: implications for cardiovascular risk reduction. J\u00a0Am Coll Cardiol 2020;76:2076\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.004.","DOI":"10.1016\/j.jacc.2020.09.004"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_031","doi-asserted-by":"crossref","unstructured":"Januzzi, JJL, Mohebi, R, Liu, Y, Sattar, N, Heerspink, H, Tefera, E, et al.. Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial. Circulation 2023;148:651\u201360. https:\/\/doi.org\/10.1161\/circulationaha.123.065251.","DOI":"10.1161\/CIRCULATIONAHA.123.065251"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_032","doi-asserted-by":"crossref","unstructured":"Yeung, AM, Huang, J, Pandey, A, Hashim, IA, Kerr, D, Pop-Busui, R, et al.. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from diabetes technology society. Progr Cardiovasc Dis 2023;79:65\u201373. https:\/\/doi.org\/10.1016\/j.pcad.2023.05.002.","DOI":"10.1016\/j.pcad.2023.05.002"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_033","doi-asserted-by":"crossref","unstructured":"Pop-Busui, R, Januzzi, JL, Bruemmer, D, Butalia, S, Green, JB, Horton, WB, et al.. Heart failure: an underappreciated complication of diabetes. A consensus report of the American diabetes association. Diabet Care 2022;45:1670\u201390. https:\/\/doi.org\/10.2337\/dci22-0014.","DOI":"10.2337\/dci22-0014"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_034","doi-asserted-by":"crossref","unstructured":"Reddy, Y, Tada, A, Obokata, M, Carter, RE, Kaye, DM, Handoko, ML, et al.. Evidenced-based application of natriuretic peptides in the evaluation of chronic Herat failure with preserved ejection fraction in the ambulatory outpatient setting. Circulation 2025;151. https:\/\/doi.org\/10.1161\/circulationaha.124.072156.","DOI":"10.1161\/CIRCULATIONAHA.124.072156"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_035","doi-asserted-by":"crossref","unstructured":"Januzzi, JL, Chen-Tournoux, AA, Christenson, RH, Doro, G, Hollander, JE, Levy, PD, et al.. ICON-RELOADED investigators. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED. Study J Am Coll Cardiol 2018;71:1191\u2013200. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.021.","DOI":"10.1016\/j.jacc.2018.01.021"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_036","doi-asserted-by":"crossref","unstructured":"Seferian, KR, Tamm, NN, Semenov, AG, Tolstaya, A, Koshkina, EV, Kransnoselsky, MI, et al.. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866\u201373. https:\/\/doi.org\/10.1373\/clinchem.2007.100040.","DOI":"10.1373\/clinchem.2007.100040"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_037","doi-asserted-by":"crossref","unstructured":"Bruins, S, Fokkema, MR, Romer, JWP, Kejongste, MJ, van der Dijs, R, van den Ouweland, J, et al.. High intraindividual variation of B-Type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052\u20138. https:\/\/doi.org\/10.1373\/clinchem.2004.038752.","DOI":"10.1373\/clinchem.2004.038752"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_038","doi-asserted-by":"crossref","unstructured":"Lee, KK, Doudesis, D, Anwar, M, Astengo, F, Chenevier-Gobeaux, C, Claessens, YE, et al.. Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. Br Med J 2022;13:e068424. https:\/\/doi.org\/10.1136\/bmj-2021-068424.","DOI":"10.1136\/bmj-2021-068424"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_039","doi-asserted-by":"crossref","unstructured":"Welsh, P, Campbell, RT, Mooney, L, Kimenai, DM, Hayward, C, Campbell, A, et al.. Reference ranges for NT-proBNP (N-Terminal Pro-B-Type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circ Heart Fail 2022;15:e009427. https:\/\/doi.org\/10.1161\/circheartfailure.121.009427.","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427"},{"key":"2025103114402230433_j_cclm-2025-0863_ref_040","doi-asserted-by":"crossref","unstructured":"Gupta, DK, de Lemos, JA, Ayers, CR, Berry, JD, Wang, TJ. Racial differences in natriuretic peptide levels: the Dallas heart study. JACC: Heart Fail 2015;3:513\u201319. https:\/\/doi.org\/10.1016\/j.jchf.2015.02.008.","DOI":"10.1016\/j.jchf.2015.02.008"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0863\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0863\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:41:35Z","timestamp":1761921695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0863\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,26]]},"published-print":{"date-parts":[[2025,10,27]]}},"alternative-id":["10.1515\/cclm-2025-0863"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0863","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}